Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
First Claim
1. A pharmaceutical composition consisting of (a) an insulin drug-oligomer conjugate comprising an insulin drug covalently coupled to an oligomeric moiety, wherein the oligomeric moiety is polyethylene glycol, (b) a bile salt, and (c) a pharmaceutically acceptable carrier.
5 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.
-
Citations
34 Claims
-
1. A pharmaceutical composition consisting of (a) an insulin drug-oligomer conjugate comprising an insulin drug covalently coupled to an oligomeric moiety, wherein the oligomeric moiety is polyethylene glycol, (b) a bile salt, and (c) a pharmaceutically acceptable carrier.
-
2. A pharmaceutical composition comprising (a) an insulin drug-oligomer conjugate comprising an insulin drug covalently coupled to an oligomeric moiety, wherein the oligomeric moiety is alkane, (b) a bile salt, and (c) a pharmaceutically acceptable carrier.
-
3. A pharmaceutical composition comprising:
-
insulin; a bile salt; and a fatty acid, wherein the fatty acid is present in an amount wherein the solubility of the bile salt in the presence of the fatty acid is greater than the solubiity of the bile salt in a corresponding composition lacking the fatty acid, wherein the bile salt is cholate and the cholate is present in the amount of about 1.5% weight/volume and the fatty acid is laurate and the laurate is present in the amount of 2% weight/volume. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
-
18. A method of treating an insulin deficiency in a subject in need of such treatment, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising (a) an insulin drug-oligomer conjugate comprising an insulin drug covalently coupled to an oligomeric moiety wherein the oligomeric moiety is lipophilic, (b) a bile salt, and (c) a pharmaceutically acceptable carrier, wherein the oligomeric moiety is alkane.
-
34. A method of treating an insulin deficiency in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition comprising (a) insulin drug-oligomer conjugate comprising an insulin drug covalently coupled to an oligomeric moiety, (b) a bile salt, and (c) a pharmaceutically acceptable carrier, by nasally administering the pharmaceutical composition to the subject.
Specification